About Us
Board of Directors
Our Directors bring a wealth of business and industry experience, having worked for companies such as Amersham, Deloitte, Citigroup and Promethera Biosciences. They are dedicated to maximising the clinical and commercial potential of our unique ECM scaffold technology.
Chairman of the Board
Eduardo was appointed as Chairman of the Board in November 2020.
He has over 25 years of senior management and board experience in the biopharmaceutical sector, having held the position of CEO at Nordic Nanovector, TiGenix and Cellerix. As CEO at TiGenix, he oversaw several financing rounds, the company’s IPO on NASDAQ, and its eventual acquisition by Takeda.
Earlier in his career, Eduardo held several senior management positions at Sanofi-Aventis and SmithKline Beecham.
He is currently Chairman of the Board at Vivet Therapeutics and a Board Member at Sutura Therapeutics.
Eduardo was President of the European Biopharmaceutical Enterprises Board of Directors between 2016 and 2018, and was also member of the Executive Committee of Alliance for Regenerative Medicine. He holds a degree in Business Administration and an MBA from INSEAD.
Chief Executive Officer and Co-Founder
Dr Giuseppe Mazza co-founded Engitix and has served as Chief Executive Officer (CEO) since the Company’s formation in 2016.
Engitix is built on Dr Mazza’s pioneering research, where he developed novel decellularisation procedures for human tissues, including whole livers, while working in the laboratory of Professor Massimo Pinzani at the Institute for Liver and Digestive Health (IDLH), Division of Medicine, University College London (UCL).
Dr Mazza was a Post-Doctoral Fellow at the UCL IDLH, where he was also responsible for operating the Tissue Engineering and Regenerative Medicine Laboratory. Dr Mazza received his PhD in Tissue Engineering and Organ Regeneration from the UCL. Dr Mazza was Director R&D at Promethera Bioscience from 2015 to 2017.
He has been involved in several international healthcare organizations, including serving on the Steering Committee of the non-profit European Haemophilia Consortium (EHC). In 2011, he founded the healthcare charity Associazione Icore ONLUS, where he served as President for six years.
Chief Financial Officer
David Dally joined Engitix as Chief Financial Officer (CFO) in November 2018.
Mr Dally has over 20 years of experience in the biotech and pharmaceutical industry, working in finance and general management across companies of varying size, financial ownership and geographical location, including in the UK, the US and Asia.
Mr Dally is an experienced executive having held the position of CEO at MerLion Pharmaceuticals since 2013, before which he was CFO from 2007. He was also consultant CEO for Reproductive Sciences Ltd from 2016 to 2018.
During his career, Mr Dally has been CFO for several companies including KuDOS Pharmaceuticals (which was sold to AstraZeneca for $210 million), Rhytec Ltd, and Dyson. He established his career as a financial leader through various roles at Amersham plc (now GE Healthcare), latterly as Vice President of finance, North America where he oversaw the merger of Amersham Life Science with Pharmacia Biotech.
David is a chartered accountant and holds a MA in Geography from the University of Cambridge.
Chief Operating Officer
Stephen Brindle has worked at Engitix as Chief Operating Officer (COO) since the Company was formed in 2016.
Before joining Engitix, he spent 8 years as Managing Partner of Technikos LLP, a medical devices venture capital fund with a long-term commercial contract with Oxford University’s Biomedical Engineering department.
Before Technikos Mr Brindle spent a decade as an equity salesman latterly with Citigroup and Goldman Sachs. Between 1991 and 1997 he worked as a management consultant, latterly at Deloitte Consulting.
He holds a BSc in Economics from LSE.
Director
Mike Platt is the co-founder and CEO of BlueCrest Capital Management, which he started in late 2000 after nearly a decade at JP Morgan.
Mike built BlueCrest into one of the world’s largest hedge fund firms; at its peak, it managed more than $35 billion in assets.
In 2015 he returned outside investors’ money, remaking BlueCrest into a family office. The firm has flourished since then, generating a 95% net return in 2020 after returns in the 50% range in 2016, 2017 and 2019.
Director
Gianluca Rosetti is Director of Strategic Planning and Business Development at Dompé farmaceutici. He joined Engitix’s Board of Directors in January 2022, following the closing of the collaboration and investment agreement with Dompé farmaceutici.
Gianluca has almost 10 years of experience in management consulting, with a specific focus in the Life Sciences. He has led strategic projects with several Fortune 500 companies that ranged from biopharmaceutical to medical devices and diagnostics.
He holds a Master Degree in Business Administration from the Università di Pavia, Italy.